No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

NCT06647953Phase 3Recruiting110 enrolled

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585Phase 3Recruiting205 enrolled

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330Phase 3Recruiting1656 enrolled

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

NCT00352534Phase 3Active Not Recruiting808 enrolled

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

NCT04994132Phase 3Active Not Recruiting118 enrolled

View all 5 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial.

Chen Lili, Xi Ling, Jiang Jie et al. · Front Med · 2022

PMID: 34181195RCT

Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.

Hoeijmakers Y M, Sweep Fcgj, Lok Car et al. · BJOG · 2020

PMID: 32141676ObservationalFull text (PMC)

Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications.

Beaty Rachel S, Bernhardt M Brooke, Berger Amanda H et al. · Pediatr Blood Cancer · 2015

PMID: 26152314Observational

Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.

Abrão Renato Antonio, de Andrade Jurandyr Moreira, Tiezzi Daniel Guimarães et al. · Gynecol Oncol · 2008

PMID: 17931696Observational

Selective thrombocytopenia in children with Wilms tumor: an immune-mediated effect of dactinomycin?

Shannon Andrew, Smith James, Nagel Kim et al. · Med Pediatr Oncol · 2003

PMID: 14515398Observational

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.

Dobson L S, Lorigan P C, Coleman R E et al. · Br J Cancer · 2000

PMID: 10789722ObservationalFull text (PMC)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report.

Das Sunil Kumar, Shahi Arun, Panthi Ram Chandra · JNMA J Nepal Med Assoc · 2022

PMID: 35633247Case ReportFull text (PMC)

Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin.

Yoshihara Hiroki, Yoshimoto Yuri, Hosoya Yosuke et al. · Pediatr Int · 2017

PMID: 28317309Case Report

Toxic epidermal necrolysis after dactinomycin and vincristine combination chemotherapy for nephroblastoma.

Liang Yuan, Yang Zhou, Xu Zi-Gang et al. · J Zhejiang Univ Sci B · 2017

PMID: 28681589Case ReportFull text (PMC)

Radiation Recall Dermatitis Secondary to Dactinomycin.

Prindaville Brea, Horii Kimberly A, Canty Kristi M · Pediatr Dermatol · 2016

PMID: 27377050Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Dactinomycin (substance)
SNOMED CT: 387353003
UMLS CUI: C0010934
RxNorm CUI: 3100
Labeler: Eugia US LLC

Clinical Data

This intervention maps to 11 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.